How have ACON shares performed in 2023?

Aclarion's stock was trading at $0.58 at the beginning of the year. Since then, ACON shares have decreased by 54.8% and is now trading at $0.2621. View the best growth stocks for 2023 here .

Are investors shorting Aclarion?

Aclarion saw a increase in short interest in November. As of November 15th, there was short interest totaling 35,300 shares, an increase of 59.7% from the October 31st total of 22,100 shares. Based on an average daily volume of 172,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.7% of the company's shares are sold short. View Aclarion's Short Interest .

When is Aclarion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ACON earnings forecast .

When did Aclarion IPO?

(ACON) raised $12 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share.

How do I buy shares of Aclarion?

Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aclarion Stock Price, News & Analysis (NASDAQ:ACON)

$0.26

-0.01 (-2.96%)

(As of 12:29 PM ET)

Compare

Today's Range: $0.26
▼
$0.30
50-Day Range: $0.26
▼
$0.57
52-Week Range: $0.25
▼
$2.37

Volume: 29,698 shs
Average Volume: 765,644 shs
Market Capitalization: $2.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Aclarion Stock (NASDAQ:ACON)

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

ACON Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACON Stock News Headlines

November 29, 2023 | americanbankingnews.com

Short Interest in Aclarion, Inc. (NASDAQ:ACON) Expands By 59.7%

November 29, 2023 | americanbankingnews.com

Aclarion (NASDAQ:ACON) and BioNexus Gene Lab (NASDAQ:BGLC) Financial Survey

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 27, 2023 | finance.yahoo.com

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

November 9, 2023 | finance.yahoo.com

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

November 6, 2023 | markets.businessinsider.com

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

October 25, 2023 | finance.yahoo.com

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

October 24, 2023 | finance.yahoo.com

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 2, 2023 | finance.yahoo.com

Aclarion Provides Updated Investor Presentation and Corporate Update

September 8, 2023 | barrons.com

Aclarion Inc.

August 25, 2023 | finance.yahoo.com

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

June 14, 2023 | finance.yahoo.com

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

June 8, 2023 | benzinga.com

Why Aclarion Stock Is Popping Today

June 8, 2023 | msn.com

ACON Skyrockets after Presentation of Nociscan Abstract

June 8, 2023 | finance.yahoo.com

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

May 30, 2023 | finance.yahoo.com

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 23, 2023 | finance.yahoo.com

Aclarion, Inc. Announces Delayed 10-Q Filing

May 23, 2023 | finance.yahoo.com

Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

May 19, 2023 | msn.com

Aclarion gets $2M debt financing

May 19, 2023 | finance.yahoo.com

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

May 10, 2023 | proactiveinvestors.com

Aclarion providing less invasive solution to treat lo back pain through augmented intelligence

April 28, 2023 | finance.yahoo.com

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

April 24, 2023 | ca.finance.yahoo.com

Aclarion, Inc. (ACON) Interactive Stock Chart - Yahoo Finance

April 24, 2023 | finance.yahoo.com

Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

April 24, 2023 | benzinga.com

Why Aclarion Shares Are Soaring Today

April 24, 2023 | msn.com

Aclarion Surges on Promising Nociscan Data in DLBP

See More Headlines

Receive ACON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACON
CUSIP: N/A
CIK: 1635077
Web: www.aclarion.com
Phone: 833-275-2266
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,070,000.00
Net Margins: -5,433.03%
Pretax Margin: -5,431.85%
Return on Equity: -724.93%
Return on Assets: -220.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.15
Quick Ratio: 0.15

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 38.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 0.94

Miscellaneous

Outstanding Shares: 8,790,000
Free Float: 6,832,000
Market Cap: $2.32 million
Optionable: Not Optionable
Beta: 1.48

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Jeffrey John Thramann M.D. (Age 58)
Executive Chairman
Comp: $318.75k
Mr. Brent Ness (Age 56)
CEO, President & Director
Comp: $418.75k
Mr. John Lorbiecki (Age 59)
Chief Financial Officer
Comp: $314.87k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ACON Stock Analysis - Frequently Asked Questions

How have ACON shares performed in 2023?: Aclarion's stock was trading at $0.58 at the beginning of the year. Since then, ACON shares have decreased by 54.8% and is now trading at $0.2621.
View the best growth stocks for 2023 here.
Are investors shorting Aclarion?: Aclarion saw a increase in short interest in November. As of November 15th, there was short interest totaling 35,300 shares, an increase of 59.7% from the October 31st total of 22,100 shares. Based on an average daily volume of 172,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.7% of the company's shares are sold short.
View Aclarion's Short Interest.
When is Aclarion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ACON earnings forecast.

When did Aclarion IPO?: (ACON) raised $12 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share.
How do I buy shares of Aclarion?: Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACON) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial